Bridging solubility between drug discovery and development

Drug Discovery Today

Volumn 17, Issue 9-10, 2012, Pages 486-495

  Di, Li ^a   Fish, Paul V ^b   Mano, Takashi ^b  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BENZIMIDAZOLE DERIVATIVE; CAFFEINE; DICLOFENAC; DIMETHYL SULFOXIDE; EFAVIRENZ; GLYCOPROTEIN P INHIBITOR; GRISEOFULVIN; HYDROCHLOROTHIAZIDE; INDOMETACIN; IVERMECTIN; LANSOPRAZOLE; MORPHINE; POLOXAMER; POLYTHIAZIDE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTHIPENDYL; SIMVASTATIN; SULFAMETOXYDIAZINE; TAMOXIFEN; THEOPHYLLINE; THIAZINE DERIVATIVE; TRICHLOMETHIAZINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; COMPUTER MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG INDUSTRY; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; REVIEW;

ANIMALS; DRUG DISCOVERY; HUMANS; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84860658314     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.11.007     Document Type: Review

References (79)

1. L. Di Drug-like property concepts in pharmaceutical design Curr. Pharm. Des. 15 2009 2184 2194
2. C.A. Lipinski Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25
3. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 2000 235 249
4. M.G. Keser, and G.M. Makara Hit discovery and hit-to-lead approaches Drug Discov. Today 11 2006 741 748
5. J.A. Wells, and C.L. McClendon Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 450 2007 1001 1009
6. M.J. Waring Lipophilicity in drug discovery Expert Opin. Drug Discov. 5 2010 235 248
7. S. Venkatesh, and R.A. Lipper Role of the development scientist in compound lead selection and optimization J. Pharm. Sci. 89 2000 145 154
8. L. Di, and E.H. Kerns Solubility issues in early discovery and HTS P. Augustijns, M. Brewster, Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics 2007 Springer 111 136
9. B. Davies, and T. Morris Physiological parameters in laboratory animals and humans Pharm. Res. 10 1993 1093 1095
10. R. Takano Quantitative analysis of the effect of supersaturation on in vivo drug absorption Mol. Pharm. 7 2010 1431 1440
11. H. Jones Modelling and PBPK simulation in drug discovery AAPS J. 11 2009 155 166
12. Y.-C. Lee An intravenous formulation decision tree for discovery compound formulation development Int. J. Pharm. 253 2003 111 119
13. M.J. Hageman Preformulation designed to enable discovery and assess developability Comb. Chem. High Throughput Screen. 13 2010 90 100
14. P. Li, and L. Zhao Developing early formulations: practice and perspective Int. J. Pharm. 341 2007 1 19
15. X.Q. Chen Discovery pharmaceutics - challenges and opportunities AAPS J. 8 2006 E402 E408
16. M. Palucki Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates J. Med. Chem. 53 2010 5897 5905
17. R.G. Strickley Solubilizing excipients in oral and injectable formulations Pharm. Res. 21 2004 201 230
18. 14C]diazepam J. Pharm. Sci. 79 1990 773 777
19. W. Loscher New injectable aqueous carbamazepine solution through complexing with 2-hydroxypropyl-beta-cyclodextrin: tolerability and pharmacokinetics after intravenous injection in comparison to a glycofurol-based formulation Epilepsia 36 1995 255 261
20. G. Cornaire Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo Int. J. Pharm. 278 2004 119 131
21. K. Bogman P-glycoprotein and surfactants: effect on intestinal talinolol absorption Clin. Pharmacol. Ther. 77 2005 24 32
22. L. Di, and E.H. Kerns Biological assay challenges from compound solubility: strategies for bioassay optimization Drug Discov. Today 11 2006 446 451
23. I.G. Popa-Burke Streamlined system for purifying and quantifying a diverse library of compounds and the effect of compound concentration measurements on the accurate interpretation of biological assay results Anal. Chem. 76 2004 7278 7287
24. L. Di, and E.H. Kerns Application of pharmaceutical profiling assays for optimization of drug-like properties Curr. Opin. Drug Discov. Dev. 8 2005 495 504
25. N. Benson NanoStore: a concept for logistical improvements of compound handling in high-throughput screening J. Biomol. Screen. 10 2005 573 580
26. K. Sugano Solubility and dissolution profile assessment in drug discovery Drug Metab. Pharmacokinet. 22 2007 225 254
27. S.R. Johnson A computational model for the prediction of aqueous solubility that includes crystal packing, intrinsic solubility, and ionization effects Mol. Pharm. 4 2007 513 523
28. W.L. Jorgensen, and E.M. Duffy Prediction of drug solubility from structure Adv. Drug Deliv. Rev. 54 2002 355 366
29. B. Faller, and P. Ertl Computational approaches to determine drug solubility Adv. Drug Deliv. Rev. 59 2007 533 545
30. E.H. Kerns, and L. Di Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization 2008 Elsevier
31. H. Zhang On-the-fly selection of a training set for aqueous solubility prediction Mol. Pharm. 4 2007 489 497
32. A.G. Leach Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure J. Med. Chem. 49 2006 6672 6682
33. M. Ishikawa, and Y. Hashimoto Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry J. Med. Chem. 54 2011 1539 1554
34. J.E. Arrowsmith Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents J. Med. Chem. 29 1986 1696 1702
35. V.C. Jordan Tamoxifen: a most unlikely pioneering medicine Nat. Rev. Drug Discov. 2 2003 205 213
36. J.T. Lundquist Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates J. Med. Chem. 53 2010 1774 1787
37. H.S. Gwak Enhanced bioavailability of piroxicam via salt formation with ethanolamines Int. J. Pharm. 297 2005 156 161
38. G.S. Paulekuhn Trends in active pharmaceutical ingredient salt selection based on analysis of the orange book database J. Med. Chem. 50 2007 6665 6672
39. L.D. Bighley Salt forms of drugs and absorption J. Swarbrick, J.C. Boylan, Encyclopedia of Pharmaceutical Technology Vol. 13 1995 Marcel Dekker, Inc 453 499
40. J. Rautio Prodrugs: design and clinical applications Nat. Rev. Drug Discov. 7 2008 255 270
41. V.J. Stella, and K.W. Nti-Addae Prodrug strategies to overcome poor water solubility Adv. Drug Deliv. Rev. 59 2007 677 694
42. P. Ettmayer Lessons learned from marketed and investigational prodrugs J. Med. Chem. 47 2004 2393 2404
43. E.F. Fiese General pharmaceutics - the new physical pharmacy J. Pharm. Sci. 92 2003 1331 1342
44. H.M. Jones Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling Clin. Pharmacokinet. 45 2006 1213 1226
45. A. Okazaki Theoretical dissolution model of poly-disperse drug particles in biorelevant media J. Pharm. Sci. 97 2008 1843 1852
46. S.I.F. Badawy Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389 Pharm. Res. 23 2006 989 996
47. K. Sugano Introduction to computational oral absorption simulation Expert Opin. Drug Metab. Toxicol. 5 2009 259 293
48. Y. Shono Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir Eur. J. Pharm. Biopharm. 79 2011 349 356
49. W. Curatolo Physical chemical properties of oral drug candidates in the discovery and exploratory development settings Pharm. Sci. Technol. Today 1 1998 387 393
50. K.C. Johnson, and A.C. Swindell Guidance in the setting of drug particle size specifications to minimize variability in absorption Pharm. Res. 13 1996 1795 1798
51. D. Engers A solid-state approach to enable early development compounds: selection and animal bioavailability studies of an itraconazole amorphous solid dispersion J. Pharm. Sci. 99 2010 3901 3922
52. D.T. Friesen Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview Mol. Pharm. 5 2008 1003 1019
53. J.S. Garrigue Self-emulsifying oral lipid-based formulations for improved delivery of lipophilic drugs Drugs Pharm. Sci. 158 2006 429 480 (Microencapsulation (2nd edition))
54. F. Kesisoglou Nanosizing - oral formulation development and biopharmaceutical evaluation Adv. Drug Deliv. Rev. 59 2007 631 644
55. N. Shan, and M.J. Zaworotko The role of cocrystals in pharmaceutical science Drug Discov. Today 13 2008 440 446
56. N.A. Meanwell The emerging utility of co-crystals in drug discovery and development Annu. Rep. Med. Chem. 43 2008 373 404
57. D.P. McNamara Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API Pharm. Res. 23 2006 1888 1897
58. D. Fleisher Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications Clin. Pharmacokinet. 36 1999 233 254
59. C.-H. Gu Predicting effect of food on extent of drug absorption based on physicochemical properties Pharm. Res. 25 2008 979 (Erratum to document cited in CA147:000758)
60. C.-H. Gu Predicting effect of food on extent of drug absorption based on physicochemical properties Pharm. Res. 24 2007 1118 1130
61. K. Sugano Prediction of food effect by bile micelles on oral drug absorption considering free fraction in intestinal fluid Eur. J. Pharm. Sci. 40 2010 118 124
62. M.S. Ku Preformulation consideration for drugs in oral CR formulation H.P. Wen, Kinam Oral Controlled Release Formulation Design and Drug Delivery 2010 John Wiley & Sons, Inc. 47 69
63. J. Zimmerman The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin) J. Clin. Pharmacol. 39 1999 1155 1161
64. S.S. Davis Physiological factors in drug absorption Ann. N. Y. Acad. Sci. 618 1991 140 149
65. G.L. Amidon A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
66. L.X. Yu Biopharmaceutics classification system: the scientific basis for biowaiver extensions Pharm. Res. 19 2002 921 925
67. J.M. Miller Identifying the stable polymorph early in the drug discovery-development process Pharm. Dev. Technol. 10 2005 291 297
68. J. Alsenz, and M. Kansy High throughput solubility measurement in drug discovery and development Adv. Drug Deliv. Rev. 59 2007 546 567
69. L.F. Huang, and W.Q. Tong Impact of solid state properties on developability assessment of drug candidates Adv. Drug Deliv. Rev. 56 2004 321 334
70. K. Sugano High throughput solubility measurement with automated polarized light microscopy analysis J. Pharm. Sci. 95 2006 2115 2122
71. B.C. Hancock, and M. Parks What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 17 2000 397 404
72. M. Pudipeddi, and A.T.M. Serajuddin Trends in solubility of polymorphs J. Pharm. Sci. 94 2005 929 939
73. E.H. Kerns In vitro solubility assays in drug discovery Curr. Drug Metab. 9 2008 879 885
74. N. Colclough High throughput solubility determination with application to selection of compounds for fragment screening Bioorg. Med. Chem. 16 2008 6611 6616
75. T.A. Fligge, and A. Schuler Integration of a rapid automated solubility classification into early validation of hits obtained by high throughput screening J. Pharm. Biomed. Anal. 42 2006 449 454
76. C.D. Bevan, and R.S. Lloyd A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates Anal. Chem. 72 2000 1781 1787
77. L. Zhou Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery J. Pharm. Sci. 96 2007 3052 3071
78. K.A. Dehring Automated robotic liquid handling/laser-based nephelometry system for high throughput measurement of kinetic aqueous solubility J. Pharm. Biomed. Anal. 36 2004 447 456
79. L. Di High throughput microsomal stability assay for insoluble compounds Int. J. Pharm. 317 2006 54 60